000796603 000__ 04603cam\a2200553M\\4500
000796603 001__ 796603
000796603 005__ 20230306143538.0
000796603 006__ m\\\\\o\\d\\\\\\\\
000796603 007__ cr\un\nnnunnun
000796603 008__ 170803s2017\\\\xx\\\\\\o\\\\\000\0\eng\d
000796603 019__ $$a999606711$$a999699775
000796603 020__ $$a9783319572253$$q(electronic book)
000796603 020__ $$a3319572253$$q(electronic book)
000796603 020__ $$z3319572245
000796603 020__ $$z9783319572246
000796603 035__ $$aSP(OCoLC)ocn999472988
000796603 035__ $$aSP(OCoLC)999472988$$z(OCoLC)999606711$$z(OCoLC)999699775
000796603 040__ $$aYDX$$beng$$cYDX$$dN$T$$dEBLCP$$dNJR$$dGW5XE$$dKOS$$dN$T$$dOCLCO$$dUAB$$dYDX$$dOCLCO
000796603 049__ $$aISEA
000796603 050_4 $$aRC644
000796603 050_4 $$aR1
000796603 08204 $$a616.99/44607548$$223
000796603 08204 $$a616.07548
000796603 24500 $$aPET/CT in Hodgkins lymphoma /$$cIrfan Kayani, editor.
000796603 260__ $$a[S.l.] :$$bSpringer,$$c2017.
000796603 300__ $$a1 online resource.
000796603 336__ $$atext$$btxt$$2rdacontent
000796603 337__ $$acomputer$$bc$$2rdamedia
000796603 338__ $$aonline resource$$bcr$$2rdacarrier
000796603 4901_ $$aClinicians' guides to radionuclide hybrid imaging, PET/CT
000796603 5050_ $$aForeword; Preface; Acknowledgements; Contents; Contributors; 1: Hodgkin Lymphoma; 1.1 Epidemiology; 1.2 Clinical Presentation; 1.3 Diagnosis; 1.4 Pathology and Classification; 1.5 Staging; 1.6 Prognostic Factors at Baseline; 1.7 Nodular Lymphocyte Predominant Hodgkin Lymphoma; Further Reading; 2: Pathology of Hodgkin Lymphoma; 2.1 NLPHL: Clinical, Biological, Morphological and Immunophenotipical Features; 2.2 cHL: Clinical, Biological, Morphological and Immunophenotipical Features; 2.3 cHL Variants; 2.3.1 Nodular Sclerosis; 2.3.2 Mixed Cellularity; 2.3.3 Lymphocyte Rich
000796603 5058_ $$a2.3.4 Lymphocyte DepletedFurther Reading; References; 3: Management of Hodgkin Lymphoma; 3.1 Baseline Evaluation; 3.2 Historical overview of HL treatment; 3.3 Upfront Treatment Modalities; 3.4 Early Stage Favourable cHL; 3.5 Early Stage Unfavourable cHL; 3.6 Treatment of Advanced-Stage Disease; 3.7 Follow-Up Evaluation; 3.8 Management of Refractory and Relapsed Disease; 3.9 Novel Agents; 3.10 Management of NLPHL; Further Reading; 4: Radiological Imaging in Lymphoma; 4.1 Introduction; 4.2 Primary Diagnosis/Staging; 4.3 Response Assessment; 4.4 The Future; References
000796603 5058_ $$a5: 18F-FDG PET/CT in Hodgkin's Lymphoma5.1 Pretreatment Assessment; 5.1.1 Staging; 5.1.2 Prognostication; 5.2 Interim Scanning; 5.2.1 Prognostication; 5.3 Response-Adapted Therapy; 5.4 End of Treatment Scanning; 5.5 PET Before High-Dose Chemotherapy or Transplant; 5.6 Surveillance; 5.7 Radiotherapy Planning; 5.8 Combined Scanning of PET/CT with Contrast-Enhanced Diagnostic Quality CT; 5.9 Scan Interpretation; References; 6: 18F-FDG PET/CT: Normal Variants, Artefacts and Pitfalls in Lymphoma; 6.1 Introduction; 6.2 General PET/CT Issues; 6.2.1 False Positive
000796603 5058_ $$a6.2.2 False Negative6.3 Anatomy Based; 6.3.1 Lymphatic Sites; 6.3.1.1 Waldeyer's ring; 6.3.1.2 Lymph Nodes; 6.3.1.3 Thymus; 6.3.1.4 Spleen; 6.3.2 Extralymphatic Sites; 6.3.2.1 CNS; 6.3.2.2 Thyroid; 6.3.2.3 Lungs; 6.3.2.4 Liver; 6.3.2.5 GI; 6.3.2.6 Renal Lymphoma; 6.3.2.7 Bone Marrow; 6.3.2.8 Skin; Further Reading; 7: PET/CT in Hodgkin's Lymphoma: Teaching Cases; 7.1 Case 1: Upstaging of Disease with PET/CT; 7.1.1 Teaching Points; 7.2 Case 2: Early Stage Unfavourable Disease; 7.2.1 Teaching Points; 7.3 Case 3: Splenic Involvement on PET/CT; 7.3.1 Teaching Points
000796603 5058_ $$a7.4 Case 4: Reactive Marrow Activity Pre-Treatment7.4.1 Teaching Points; 7.5 Case 5: Bone Marrow Involvement; 7.5.1 Teaching Points; 7.6 Case 6: Brown Fat Activity; 7.6.1 Teaching Points; 7.7 Case 7: Thymic Hyperplasia; 7.7.1 Teaching Points; 7.8 Case 8: Reactive Bone Marrow and Spleen Activation; 7.8.1 Teaching Points; 7.9 Case 9: Metabolic Remission; 7.9.1 Teaching Points; 7.10 Case 10: Interim PET Scan with Uptake Score of 3; 7.10.1 Teaching Points; 7.11 Case 11: Interim PET Scan with Uptake Score of 4; 7.11.1 Teaching Points
000796603 506__ $$aAccess limited to authorized users.
000796603 588__ $$aDescription based on print version record.
000796603 650_0 $$aHodgkin's disease$$xTomography.
000796603 650_0 $$aTomography, Emission.
000796603 650_0 $$aMedicine.
000796603 650_0 $$aNuclear medicine.
000796603 650_0 $$aOncology.
000796603 7001_ $$aKayani, Irfan.
000796603 77608 $$iPrint version:$$z3319572245$$z9783319572246$$w(OCoLC)981691089
000796603 830_0 $$aClinicians' guides to radionuclide hybrid imaging.$$pPET/CT.
000796603 852__ $$bebk
000796603 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-57225-3$$zOnline Access$$91397441.1
000796603 909CO $$ooai:library.usi.edu:796603$$pGLOBAL_SET
000796603 980__ $$aEBOOK
000796603 980__ $$aBIB
000796603 982__ $$aEbook
000796603 983__ $$aOnline
000796603 994__ $$a92$$bISE